drugset / Trial / NCT00551733

Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00551733

Phase 3 Terminated 450 enrolled CTI BioPharma
RandomizedOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as carboplatin, paclitaxel, and paclitaxel poliglumex, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving carboplatin together with paclitaxel poliglumex is more effective than giving carboplatin together with paclitaxel in treating non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying carboplatin and paclitaxel poliglumex to see how well they work compared with carboplatin and paclitaxel in treating women with stage III, stage IV, or recurrent non-small cell lung cancer.

Timeline

Start
2007-08
Primary completion
2007-12-25
Completion
2007-12-25

Drugs

EvaluationDrugModalityDoseRoute
Comparator Paclitaxel Small molecule 225 mg/m2 Intravenous
Subject paclitaxel poliglumex Other / unclassified 210 mg/m2 Intravenous
Background Carboplatin Small molecule 6 unknown Intravenous

Indications